Rani Therapeutics Holdings Inc (RANI)

RA Capital Management, L.P. and its affiliates reported a 9.99% beneficial ownership in Rani Therapeutics Holdings, Inc. (RANI) Class A common stock as of June 30, 2026. This ownership is capped at 11,530,414 shares due to "Beneficial Ownership Blockers" in pre-funded and common warrants, preventing exercise beyond the 9.99% threshold. The filing details the direct holdings of RA Capital Healthcare Fund, L.P., warrant exercisability, and the calculation of the ownership percentage.

Rani Therapeutics (RANI) reported its Q2 2026 financial results, highlighting a $20 million gross raise through a Class A share and pre-funded warrant financing in May 2026, and contract revenue of $1.7 million for the quarter, primarily from a collaboration with Chugai. The company's cash, cash equivalents, and marketable securities totaled $53.4 million, which is expected to fund operations for at least twelve months. Rani also announced positive initial Phase 1a data for its RT-114 obesity program, showing oral bioavailability exceeding 150% compared to subcutaneous dosing, and entered a new research collaboration with PegBio.

Rani Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical trials and corporate development. The company announced positive initial Phase 1a data for RT-114, confirming high oral bioavailability, and expanded its obesity pipeline through a new collaboration with PegBio. Rani also completed a $20 million direct offering and made key executive and board appointments.

Rani Therapeutics announced its second-quarter 2026 financial results, highlighting significant progress in advancing its RaniPill® oral delivery platform. Key achievements include positive initial Phase 1a data for RT-114, showing high oral bioavailability, a new collaboration with PegBio for obesity treatments, and the completion of a $20 million direct offering. The company also reported a net loss of $8.4 million for the quarter and expects its current cash to fund operations through 2027.

Rani Therapeutics reported its Q2 2026 financial results, including a net loss of $8.4 million and contract revenue of $1.7 million, with cash reserves of $53.4 million expected to fund operations through 2027. The company announced positive initial Phase 1a data for its oral RT-114, showing over 150% bioavailability compared to subcutaneous dosing, and entered a collaboration with PegBio to expand its obesity pipeline. Rani also completed a $20 million direct offering and made key executive and board appointments.